|
Nov 29
|
SELLAS Life Sciences Reaches Target Enrollment ex-China in Phase 3 REGAL Trial of Galinpepimut-S in Acute Myeloid Leukemia
|
|
Jul 15
|
Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely
|
|
Apr 26
|
SELLAS Life Sciences Announces Abstract Accepted for Presentation at ASCO 2023 Annual Meeting
|